Abstract In addition to their role in desensitization and internalization of G protein-coupled receptors (GPCRs), b-arrestins are essential scaffolds linking GPCRs to Erk1/2 signaling. However, their role in GPCR-operated Erk1/2 activation differs between GPCRs and the underlying mechanism remains poorly characterized. Here, we show that activation of serotonin 5-HT 2C receptors, which engage Erk1/2 pathway via a b-arrestin-dependent mechanism, promotes MEKdependent b-arrestin2 phosphorylation at Thr 383 , a necessary step for Erk recruitment to the receptor/b-arrestin complex and Erk activation. Likewise, Thr 383 phosphorylation is involved in barrestin-dependent Erk1/2 stimulation elicited by other GPCRs such as b 2 -adrenergic, FSH and CXCR4 receptors, but does not affect the b-arrestin-independent Erk1/2 activation by 5-HT 4 receptor. Collectively, these data show that b-arrestin2 phosphorylation at Thr 383 underlies barrestin-dependent Erk1/2 activation by GPCRs.
Introduction
Arrestins were initially named on the basis of their ability to turn-off the coupling of G protein-coupled receptors (GPCRs) to G proteins and thereby inhibit G protein-dependent GPCR signaling. Over the last decade, it has become evident that b-arrestins are also important signal transducers and that a number of biological functions exerted by GPCRs are mediated by b-arrestin-dependent signaling (Shenoy and Lefkowitz, 2011; Lefkowitz and Shenoy, 2005; Latapy and Beaulieu, 2013; Beaulieu et al., 2007) . b-arrestins act as multifunctional scaffolds that recruit multiple signaling molecules, such as the core Extracellular signal-regulated kinase Erk1/2 signaling module, composed of Raf1, MAP kinase kinase MEK1 and MAP kinases Erk1/2, a process leading to Erk1/2 activation DeFea et al., 2000; Luttrell et al., 2001) . Typically, most GPCRs induce temporally distinct and spatially segregated G protein-dependent and b-arrestin-dependent activation of Erk: G protein-mediated Erk activation is rapid and transient, reaching a maximal level within a few minutes and is followed by translocation of activated Erk into the nucleus to promote gene transcription and cell proliferation. In contrast, b-arrestin-mediated Erk1/2 activation is slower in onset, requiring 5-10 min to reach maximal level, persists more than 1 hr and mainly occurs in the cytosol Ahn et al., 2004a; Shenoy et al., 2006) . However, Erk1/2 signaling elicited by certain GPCRs does not fit this classic bimodal activation pattern: for example, the activation of Erk1/2 pathway by 5HT 2C receptors is entirely dependent on b-arrestins (Labasque et al., 2008) , whereas the engagement of this pathway by the 5-HT 4 receptor does not require b-arrestin recruitment (Barthet et al., 2007) . In addition, some GPCRs such as m-opioid receptor induce b-arrestin-dependent activation of Erk1/2 that translocate to the nucleus (Zheng et al., 2008) .
Accumulating evidence indicates that b-arrestin recruitment to GPCRs and engagement of barrestin-mediated signaling depend on both receptor conformational state and a complex pattern of receptor phosphorylation elicited by GPCR kinases (GRKs) Shukla et al., 2011) . This phosphorylation barcode is translated into specific b-arrestin conformations that dictate selective signaling and the nature of b-arrestin intracellular functions. Another mechanism that might underlie b-arrestin dependency of receptor-operated signaling is the phosphorylation of b-arrestins themselves. Several phosphorylated residues have been identified in the b-arrestin sequences, including Ser 412 for b-arrestin1 (Lin et al., 1997; Barthet et al., 2009; Lin et al., 1999) and Thr 276 , Ser 361 and Thr 383 for b-arrestin2 (Lin et al., 2002; Paradis et al., 2015; Kim et al., 2002) . These phosphorylation events affect GPCR internalization and/or sequestration and, consequently, steady-state level of GPCR cell-surface expression: phosphorylation of b-arrestin1 at Ser 412 by Erk1/2 as well as the phosphorylation of b-arrestin2 at both Ser 361 and Thr 383 reduce their ability to induce internalization of b 2 -adrenergic receptor (Lin et al., 1997 (Lin et al., , 1999 (Lin et al., , 2002 , whereas phosphorylation of b-arrestin2 at Ser 14 and Thr 276 promotes intracellular sequestration of CXCR4
receptor (Paradis et al., 2015) . These results indicate that b-arrestin2 phosphorylation exerts contrasting effects on GPCR trafficking that may depend on the nature of the phosphorylated residue(s) and of the GPCR. Another phosphorylated site (Ser 178 ) was identified in rat/mouse b-arrestin2 and its phosphorylation state affects endosomal trafficking of various GPCRs (Khoury et al., 2014) . However, this serine residue is not conserved in other species including human, suggesting different regulations of endosomal GPCR trafficking between species. Additional phosphorylated residues have been found on b-arrestin2 in large-scale phosphoproteomics screens, but their functional relevance remains to be established (Pighi et al., 2011; Sharma et al., 2014; Ballif et al., 2008; Villén et al., 2007; Choudhary et al., 2009; Jørgensen et al., 2009) . In contrast to its role in GPCR trafficking, the influence of b-arrestin phosphorylation on GPCR-operated b-arrestin-dependent signaling such as Erk1/2 activation remains unexplored. Here, we investigated the impact on b-arrestin1 and 2 phosphorylation of expression/stimulation of 5-HT 2C and 5-HT 4 receptors, two GPCRs that differ in their b-arrestin dependency to promote Erk1/2 activation, using high-resolution mass spectrometry. We identified several previously described as well as novel phosphorylated residues on b-arrestin2, while only one phosphorylated site was found on b-arrestin1. Of these, only phosphorylation of b-arrestin2 at Thr 383 exhibited a strong increase upon 5-HT 2C receptor stimulation. Furthermore, Thr 383 was poorly phosphorylated in cells expressing 5-HT 4 receptor and its phosphorylation was only slightly enhanced by agonist treatment. These findings prompted functional studies to evaluate the influence of this phosphorylation event in Erk1/2 phosphorylation elicited by stimulation of 5-HT 2C receptor and other GPCRs known to engage Erk signaling in a b-arrestin-dependent manner, in comparison with 5-HT 4 receptor stimulation, which induces Erk1/2 activation through a b-arrestin-independent mechanism. Only one phosphorylated site (Thr 374 ) was identified on b-arrestin1, but the corresponding phosphorylated peptide was only detected in cells expressing 5-HT 4 receptor, and with a low phosphorylation index, as estimated by dividing the MS signal intensity of the phosphorylated peptide by the sum of MS signal intensities of the phosphorylated and the corresponding non-phosphorylated peptide ( Figure 1 -source data 1, see also the fragmentation spectrum that pinpoints the position of the phosphorylation site on Figure 1-figure supplement 3) . Moreover, label-free quantification of the MS signal of this phosphorylated peptide in cells treated or not with 5-HT indicated that Thr 374 phosphorylation is not affected by 5-HT exposure (Figure 1-source data 1) . Previous studies using a phosphorylated site-specific antibody have identified Ser 412 as an additional phosphorylated residue on b-arrestin1 (Lin et al., 1997; Barthet et al., 2009; Lin et al., 1999) . They also indicated that Ser 412 phosphorylation state is modified upon activation of various GPCRs, including the 5-HT 4 receptor (Barthet et al., 2009 plasmid. We thus generated a polyclonal antibody that specifically recognizes b-arrestin2 phosphorylated at Thr 383 (see Figure 2C and Figure 2 -source data 1). Western blot experiments using this antibody showed that 5-HT 2C receptor stimulation induces a substantial increase in endogenous barrestin2 phosphorylation at Thr 383 , while activation of the 5-HT 4 receptor did not affect its phosphorylation level ( Figure 1C and receptor that parallels the b-arrestin2-dependent receptor-operated activation of Erk1/2 ( Figure 1 and Figure 1 -figure supplement 1), we paid particular attention to the phosphorylation of this residue, which is located in an unfolded region of the carboxy-terminal region of b-arrestin2 easily accessible to protein kinases ( Figure 1A) . In an effort to identify kinase(s) involved in its phosphorylation, we first used Group-based Prediction System (GPS, v2.1), an algorithm for kinase consensus search that classifies protein kinases into a hierarchical structure with four levels and trains against the PhosphoELM database, in order to determine individual false discovery rates for each of them (Xue et al., 2008) . GPS search revealed that Thr 383 is a strong consensus for phosphorylation by casein kinase 2 (CK2 GPS score 5.3), consistent with previous findings (Lin et al., 2002; Kim et al., 2002) . with a GPCR can interact with different signaling proteins including c-Src and several proteins of the Erk signaling module (Raf/MEK/Erk), and that these interactions depend on b-arrestin conformational state (Xiao et al., 2004; Gurevich and Gurevich, 2003) .
In line with these findings, we have recently modeled the complex between a GPCR, b-arrestin2, c-Src and the Erk module from the 3D structure of each partner, using the Protein-Protein cOmplexes 3D structure pRediction (PRIOR) docking algorithm, and validated experimentally the previously unknown interaction regions (Bourquard et al., 2015) . This model predicts that the unfolded C-terminal part of b-arrestin comprising Thr 383 is located in the vicinity of the MEK active site ( confirm the ability of MEK to directly phosphorylate this residue, we performed an in vitro kinase assay using purified active MEK1 and YFP-b-arrestin2 purified from transfected HEK-293 cells as substrate, followed by Western blotting using the anti-phospho-Thr 383 b-arrestin2 antibody. MEK1
induced a strong elevation in the immunoreactive signal that was abolished by adding U0126 in the incubation medium ( Figure 2C ). As expected, no increase in immunoreactive signal was observed in experiments using YFP-Thr 383 Ala b-arrestin2 mutant as substrate, thus validating the specificity of the antibody for b-arrestin2 phosphorylated at Thr 383 . This result was confirmed using a radioactive kinase assay, which also showed comparable efficacy of MEK1 to promote phosphorylation of Impact of Thr 383 phosphorylation upon b-arrestin2 conformational changes elicited by 5-HT 2C and 5-HT 4 receptor stimulation b-arrestins are known to undergo important conformational rearrangements upon translocation to agonist-stimulated GPCRs that are essential for their downstream action (Xiao et al., 2004; Gurevich and Gurevich, 2014) . To explore the impact of Thr 383 phosphorylation on conformational changes of b-arrestin2 induced by 5-HT 2C receptor activation vs. 5-HT 4 receptor activation, we used an optimized intramolecular BRET biosensor consisting of b-arrestin2 sandwiched between the Renilla green fluorescent protein (RGFP) and the Renilla luciferase variant Rluc8 (Kamal et al., 2009; Charest et al., 2005) . When b-arrestin2 conformation changes, the distance between Rluc8 and RGFP increases or decreases leading to a BRET signal decrease or increase. Treating cells coexpressing 5-HT 2C receptor and WT RLuc8-b-arrestin2-RGFP with 5-HT increased the BRET signal. No BRET increase was detected upon agonist exposure in cells coexpressing the receptor and T 383 A RLuc8-barrestin2-RGFP ( Figure 3E) . Mutation of Thr 383 into aspartate in RLuc8-b-arrestin2-RGFP also resulted in an increase in BRET signal to a level similar to the one measured in cells expressing the wild type probe and exposed to 5-HT, and 5-HT treatment did not further enhance this elevated BRET signal ( Figure 3E ). b-arrestin2 phosphorylation at Thr 383 is essential for Erk1/2 translocation to the 5-HT 2C receptor/b-arrestin2 complex
As previously hypothesized, it can be envisioned that the unfolded C-terminal region of b-arrestin2 occupies the docking site of Erk1/2 located in the vicinity of MEK catalytic site in the receptor/barrestin2 complex (Figure 2A arrestin2 down-regulation upon activation of Erk1/2 by the three GPCRs examined, suggesting that phosphorylation of this residue is a general mechanism underlying b-arrestin-dependent Erk1/2 activation by GPCRs.
Discussion
In this study, using high-resolution mass spectrometry combined with label-free quantification, we provide for the first time a comprehensive characterization of phosphorylated sites on b-arrestins 1 and 2 in living cells. We also explored the influence on their phosphorylation status of 5-HT 2C and 5-HT 4 receptors, two model GPCRs that engage the Erk1/2 pathway through b-arrestin-dependent and independent mechanisms, respectively. We identified one phosphorylated site on b-arrestin1 and six on b-arrestin2, including three previously identified residues ( ) are conserved in b-arrestin1, but we did not detect the corresponding phosphorylated peptides in b-arrestin1. Although MS/MS does not allow exhaustive identification of peptides present in complex samples, it is unlikely that our analyses, which covered about of 85% of the sequence of both arrestins, missed these phosphorylated residues on b-arrestin1 or any other robustly phosphorylated residues on both arrestins. Therefore, our results corroborate previous findings which identified much more phosphorylated residues on b-arrestin2 than on b-arrestin1 and suggest that b-arrestin2 is phosphorylated at higher stoichiometry, compared with b-arrestin1. Our analyses did not detect, even in 5-HT-treated cells, another site conserved between both b-arrestins (Ser 276 ) that was previously reported as being phosphorylated by recombinant active Erk1 in an in vitro phosphorylation assay followed by MS/MS analysis (Paradis et al., 2015) . This suggests that in cells expressing 5-HT 2C or 5-HT 4 receptor, the level of Erk1/2 activity and/or the molecular environment of this serine residue do not allow its phosphorylation at high stoichiometry. Amongst b-arrestin2 phosphorylated residues identified in the present study, only the phosphorylation of Thr 383 was modulated upon agonist stimulation of 5-HT 2C receptor and, to a much lesser extent, 5-HT 4 receptor. In silico search of kinase-specific phosphorylation sites in b-arrestin2 sequence identified Thr 383 as a strong consensus for phosphorylation by CK2, consistent with previous findings which showed that Thr 383 is phosphorylated by CK2 in vitro (Kim et al., 2002) , and by MEK. Our results indicate that MEK rather than CK2 is involved in Thr 383 phosphorylation elicited by 5-HT 2C receptor stimulation in living HEK-293 cells, consistent with our docking model of the receptor/b-arrestin2/MEK complex, which predicts that the unfolded C-terminal part of b-arrestin comprising Thr 383 is located in the vicinity of MEK active site.
In an effort to characterize the functional impact of Thr 383 phosphorylation, we found that its replacement by alanine or aspartate to inhibit or mimic its phosphorylation, did not modify barrestin2 translocation to the receptor nor agonist-induced receptor internalization. This result corroborates previous observations indicating that the sole substitution of Thr 383 to aspartate or alanine does not affect isoproterenol-induced b 2 -adrenergic receptor internalization (Lin et al., 2002) . In fact, only the double substitution of Ser 361 and Thr 383 to aspartate inhibited agonist-induced receptor internalization, an effect reflecting the reduced ability of this double b-arrestin mutant to bind to clathrin (Lin et al., 2002) . It is likely that the phosphorylation stoichiometry of Ser 361 and Thr 383 in our experimental conditions, including cells exposed to 5-HT, does not allow such a regulation. Moreover, previous studies showed that b 2 -adrenergic receptor stimulation decreases rather than enhances the phosphorylation of these residues (Lin et al., 2002; Kim et al., 2002) . Accordingly, these studies and our results suggest that b-arrestin2 phosphorylation at Thr 383 might only have a minor influence on GPCR trafficking. In contrast, expressing Thr 276 Ala or Ser 14 Ala b-arrestin2 mutants in b-arrestin1/2 knockout cells fails to restore agonist-induced CXCR4 receptor sequestration while expressing a b-arrestin2 mutant harboring an aspartate at these positions is sufficient to decrease cell surface localization in the absence of agonist (Paradis et al., 2015) . This suggests that Thr 276 and/or Ser 14 phosphorylation rather than Thr 383 phosphorylation might be critical for agonistinduced intracellular sequestration of some GPCRs. Our results establish a causal link between Thr 383 phosphorylation and b-arrestin2 conformational rearrangements, assessed by double brilliance BRET assay, elicited upon 5-HT 2C receptor stimulation. They corroborate previous observations suggesting that conformational changes of b-arrestin do not directly result from its binding to phosphorylated GPCRs, but from downstream events, such as subsequent recruitment of b-arrestin interacting proteins (Charest et al., 2005; Xiao et al., 2007) . Nonetheless, Thr 383 phosphorylation dependency of b-arrestin2 conformational changes seems to also depend on the nature of the GPCR it associates with, as the increase in intramolecular BRET signal measured upon 5-HT 4 receptor stimulation was not affected by substituting Thr 383 by alanine or by aspartate. The present study also identified Thr 383 phosphorylation as an essential molecular step allowing Erk1/2 translocation to the 5-HT 2C /b-arrestin2/MEK complex and subsequent activation of Erk1/2 signaling upon 5-HT 2C receptor stimulation. Based on the current experimental results and our previously validated docking model (Bourquard et al., 2015) , we propose a molecular mechanism which might explain the role of Thr 383 phosphorylation in recruitment and activation of Erk at the activated b-arrestin. In the crystal structures of both b-arrestin1 (PDB 1G4R) (Han et al., 2001 ) and b-arrestin2 (PDB 3P2D) (Zhan et al., 2011) , the segment of the C-terminal tail comprising residues 385-393 folds as a b-strand, which associates with the first N-terminal b-strand. The crystal structure of barrestin1 in complex with a C-terminal peptide of the V2 receptor (PDB 4JQI) (Shukla et al., 2013) , also shows that the C-terminal peptide of the receptor occupies the same location as the 385-393 segment of the inactive b-arrestin. Consequently, a drastic conformational change of the 385-393 barrestin segment is necessary for the correct association of b-arrestin with the receptor. Furthermore, our previously reported docking model shows that the C-terminal region of the receptor is sandwiched between b-arrestin and Erk, and thus has to associate with b-arrestin before its association with Erk (Bourquard et al., 2015) . Finally, although Thr 383 is not present in the different structures of b-arrestins, the position of Asp 385 shows that Thr 383 is located in the vicinity of b-arrestinbound MEK's active site, where it can be phosphorylated. In our model (Figures 2 and 6 ), Thr 383 phosphorylation by MEK takes place within the ligand-dependent receptor/b-arrestin/Raf/MEK complex. We propose that this phosphorylation triggers the conformational change of the 350-393 region, allowing the interaction of b-arrestin with the receptor C-terminal domain, the subsequent binding of Erk to the complex and its activation by MEK. This mechanism, initially established for the 5-HT 2C receptor, a GPCR which elicits Erk1/2 signaling mainly through a b-arrestin-dependent mechanism, appears to be conserved among GPCRs that induce Erk1/2 activation through the classic dual mechanism involving both G proteins and b-arrestins, such as b-adrenergic, CXCR4 and FSH receptors. Actually, the sustained Erk1/2 phosphorylation induced by agonist stimulation of these receptors was strongly reduced in cells expressing the Thr 383 Ala b-arrestin2 mutant. In contrast, substitution of Thr 383 by aspartate increased the basal level of Erk1/2 phosphorylation, suggesting that phosphorylated b-arrestin2 can recruit and subsequently activate Erk1/2 in absence of receptor stimulation. As expected, 5-HT 4 receptor-operated Erk1/2 phosphorylation, which is b-arrestin-independent, was not affected by substituting Thr 383 by alanine.
This result is consistent with the low Thr 383 phosphorylation level measured in cells expressing 5-HT 4
receptors, compared with cells expressing 5-HT 2C , and suggests that Thr 383 phosphorylation might be a key molecular event governing b-arrestin dependency of Erk1/2 pathway engagement by GPCRs. In conclusion, our study identifies MEK-elicited b-arrestin2 phosphorylation at Thr 383 as a key molecular event underlying b-arrestin-dependent Erk1/2 activation by GPCRs. Thr 383 phosphorylation has recently been involved in b-arrestin2 association with transient receptor potential vanilloid 1 (TRPV1) at the plasma membrane, which is critical for its role in regulating receptor desensitization (Por et al., 2013) . This underscores the potentially high influence of Thr 383 phosphorylation upon various b-arrestin2 functions related or not to GPCRs, while the phosphorylation of other residues (Ser 14 and Thr 276 ) might govern steady state level of GPCR cell-surface expression (Paradis et al., 2015) . This also indicates that b-arrestin2 can integrate upstream signals not only via its conformational changes upon association with receptors but also through a complex phosphorylation pattern that dictates downstream signaling events and the associated physiological functions.
Materials and methods

Materials
Human Embryonic Kidney-293 (HEK-293) N type cells (RRID:CVCL_0045) were from the American Type Culture Collection ( anassas, VI, ATCC, CRL-1573). All experiments of the study were performed using a previously characterized batch of cells (Isolate #3) . Their negative mycoplasma status was analyzed every month using the MycoAlert Mycoplasma Detection Kit (Lonza, Switzerland). Culture media were from Invitrogen (Carlsbad, CA). The siRNA used to target b-arrestin2 (5'-AAGGACCGCAAAGUGUUUGUG-3', position 201-221) and the control siRNA (5'-AAUUCUCCGAACGUGUCACGU-3') were from Dharmacon (Lafayette, CO)and the GeneSilencer siRNA transfection reagent from Genlantis (San Diego, CA). pEYFP-bARR2, pEYFP-bARR1 and pcDNA3-Rluc-bARR2 plasmids were kindly provided by Dr. Michel Bouvier (University of Montreal). pcDNA3-Rluc-bARR2
T383A and pcDNA3-Rluc-bARR2 T383D constructs were generated by site directed mutagenesis from the pcDNA3-Rluc-bARR2 vector. The pCMV-Rluc8-bARR2-RGFP construct used to monitor b-arrestin2 conformational changes (double brilliance assays), previously described in (Kamal et al., 2009) , was a generous gift from Dr. Ralph Jockers (Institut Cochin, Paris). pCMV-Rluc8-bARR2 T383A -RGFP and pCMV-Rluc8-bARR2 T383D -RGFP were generated by site directed mutagenesis from this vector. Plasmids encoding Myc-5-HT 2C -YFP receptor (pEYFP-N1-Myc-5-HT 2C ) and Myc-5-HT 4 -YFP receptor (pEYFP-N1-Myc-5-HT 4 ) were generated from pRK5-Myc-5-HT 2C-VGV and pRK5-Myc-5-HT 4 plasmids (Chanrion et al., 2008; Pellissier et al., 2011) , respectively. The pcDNA3.1-Flag-FSHR plasmid was described in Tranchant et al. (2011) . The plasmid encoding catalytically inactive dominant inhibitory mutant of MEK1 (K97A) was a generous gift from Dr. Robert J. Lefkowitz (Duke University Medical Center, Durham, NC) . The mouse anti-phospho-Thr 202 /Tyr 204 -Erk1/2 antibody (Clone E.4, AB_2636855), the rabbit anti-GAPDH antibody (RRID:AB_10167668) and the goat anti-integrin b1 antibody (RRID:AB_2128200) were from Santa Cruz Biotechnology (Dallas, TX) , the rabbit anti-pan arrestin antibody (RRID:AB_ 303409) and the mouse anti-b-arrestin2 antibody (RRID:AB_2060273) from Abcam (UK), the rabbit anti-Erk1/2 antibody (RRID:AB_330744), the rabbit anti-Elk1 (RRID:AB_2277936) and the rabbit antiphospho-Ser 383 -Elk1 (RRID:AB_2099016) from Cell Signaling Technology (Danvers, MA), the rabbit anti-GFP antibody (RRID:AB_221569) from Invitrogen, and the rabbit anti-Flag (RRID:AB_439687) and mouse anti-Myc (RRID:AB_439694) antibodies from Sigma Aldrich (Saint-Louis, MO). The antiphosphoThr 383 -b-arrestin2 antibody was generated by immunizing rabbits with the synthetic CDTNYAT(PO 3 H 2 )DDDIVF peptide coupled to Keyhole Limpet Hemocyanin (KLH, Cisbio Bioassays, Codolet, France). Antibodies were purified by two consecutive affinity chromatographies. A first chromatography against the immobilized phosphorylated CDTNYAT(PO 3 H 2 )DDDIVF peptide as bait bound antibodies recognizing both phosphorylated and non-phosphorylated forms of the peptide. The retained fraction was then eluted and used for a second chromatography against the immobilized non-phosphorylated CDTNYATDDDIVF peptide as bait. We considered that the nonretained fraction contains antibodies recognizing b-arrestin2 phosphorylated at Thr 383 . (Ahn et al., 2004b) , we also estimated levels of b-arrestin1 and b-arrestin2 as~1600 pmol/ mg protein and~300 pmol/mg protein in cells transfected with pEYFP-bARR1 and pEYFP-bARR2 plasmids, respectively, by Western blotting using the rabbit anti-pan arrestin antibody. For experiments using siRNAs, cells were simultaneously transfected with control or b-arrestin2 siRNA (150 nmol/10 6 cells) and plasmids encoding receptors of interest, using the GeneSilencer reagent.
Quantitative mass spectrometry analysis of b-arrestin1 and b-arrestin2 phosphorylation HEK-293 cells transiently co-expressing YFP-tagged b-arrestin1 or YFP-tagged b-arrestin2 and either Myc-5-HT 2C or Myc-5-HT 4 receptor were starved of serum for 4 hr, challenged with either vehicle or 5-HT and lysed in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP40, 0.4% dodecylmaltoside, 10 mM sodium fluoride, 1 mM sodium pyrophosphate, 50 mM b-glycerophosphate, 2 mM sodium orthovanadate and a protease inhibitor cocktail (Roche, Switzerland). Samples were centrifuged at 15,000 Â g for 15 min at 4˚C and b-arrestins were immunoprecipitated with agarose-conjugated GFP trap (ChromoTek, Germany). After reduction with dithiothreitol (10 mM, 30 min at 60˚C) and alkylation with iodoacetamide (50 mM, 45 min at 25˚C), immunoprecipitated b-arrestins were resolved by SDS-PAGE and digested in-gel overnight at 25˚C with trypsin (1 mg, Gold, Promega, Madison, WI). Peptides were analyzed by nano-LC-FT-MS/MS using a LTQ Orbitrap Velos mass spectrometer coupled to an Ultimate 3000 HPLC (Thermo Fisher Scientific, Waltham, MA). Desalting and pre-concentration of samples were performed on-line on a Pepmap precolumn (0.3 mm Â 10 mm, Dionex). A gradient consisting of 2-40% buffer B (3-33 min), 40-80% B (33-34 min), 80-0% B (49-50 min), and equilibrated for 20 min in 0% B (50-70 min) was used to elute peptides at 300 nL/min from a Pepmap capillary (0.075 mm Â 150 mm) reversed-phase column (Thermo Fisher Scientific). Mass spectra were acquired using a top-10 collision-induced dissociation (CID) datadependent acquisition (DDA) method. The LTQ-Orbitrap was programmed to perform a Fourier transform (FT) full scan (60,000 resolution) on 400-1,400 Th mass range with the top ten ions from each scan selected for LTQ-MS/MS with multistage activation on the neutral loss of 24.49, 32.66 and 48.99 Th. FT spectra were internally calibrated using a single lock mass (445.1200 Th). Target ion numbers were 500,000 for FT full scan on the Orbitrap and 10,000 MSn on the LTQ. Precursor mass and top 6 per 30 Da windows peak lists were extracted from MS2 using MSconvert 3.0 and searched with Mascot 2.4 (RRID:SCR_014322) against the same human Complete Proteome Set database (RRID:SCR_002380), cysteine carbamidomethylation as a fixed modification and phosphorylation of Ser, Thr and Tyr as variable modifications, 7 ppm precursor mass tolerance, 0.5 Da fragment mass tolerance and trypsin/P digestion. MS2 spectra matching phosphorylated peptides with ion score over 15 were manually inspected for unique transitions that pinpoint the position of phosphorylation sites. Ion signals corresponding to phosphorylated peptides were quantified from the maximal intensities measured in their ion chromatograms manually extracted using Qual browser v2.1 (Thermo Fisher Scientific) with a tolerance of 5 ppm for mass deviation, and normalized to signals of their non-phosphorylated counterparts. For each identified phosphorylated residue, a phosphorylation index (maximal intensity observed in the phosphorylated peptide extracted ion chromatogram/sum of the maximal intensities observed in the phosphorylated and the non-phosphorylated peptide extracted ion chromatograms) was calculated.
In vitro kinase assays YFP-tagged b-arrestin2 (wild type or Thr 383 Ala mutant) was purified from HEK-293 cells using GFP trap beads, as described in the previous section. For kinase assay, 10 mL of purified fractions containing~1 mg b-arrestin2 were incubated for 10 min at 37˚C in 5 mL kinase buffer (25 mM MOPS, pH 7.2, 12.5 mM b-glycerophosphate, 25 mM MgCl 2 , 5 mM EGTA, 2 mM EDTA, 0.25 mM DTT) in absence or presence of 5 mL active MEK1 (EE, 0.025 mg/mL, Sigma Aldrich). Kinase reaction was started by adding 5 mL ATP (250 mM) and was stopped by adding Laemmli buffer. b-arrestin2 phosphorylation at Thr 383 was analyzed by Western blotting using the purified anti-phospho-Thr 383 -barrestin2 antibody. For radioactive kinase assay, 10 ml of purified fractions containing~1 mg YFP-barrestin2 or 1 mg of non-activated, purified GST-tagged Erk2 (Sigma Aldrich) were incubated for 10 min at 37˚C in 5 mL kinase buffer in presence of active MEK1 and [g-32 P]-ATP (50 mM, 2 mCi/nmol).
Proteins were separated by SDS-PAGE and stained with colloidal Coomassie. Gels were dried and exposed for autoradiography. Radioactive bands corresponding to b-arrestin2 and Erk2 were excised and radioactivity was measured by b-scintillation counting.
Western blotting
Proteins, resolved onto 10% polyacrylamide gels, were transferred to Hybond C nitrocellulose membranes (GE Healthcare, UK). Membranes were immunoblotted with primary antibodies (anti phospho-Thr 202 /Tyr 204 -Erk1/2, 1:1000; anti Erk1/2, 1:1000; anti-Flag, 1:1000; Anti-GFP, 1:1000; anti-Myc, 1:1000; anti-phospho-Thr 383 -b-arrestin2, 1:5000; anti-b-arrestin2, 1:1000; anti-pan arrestin, 1/1000) and then with either anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:5000, GE Healthcare). Immunoreactivity was detected with an enhanced chemiluminescence method (ECL plus detection reagent, Perkin Elmer, Waltham, MA). Immunoreactive bands were quantified by densitometry using the ImageJ software. In protein phosphorylation analyses, the amount of each phosphoprotein was normalized to the corresponding total protein signal.
ELISA
Quantification of cell surface expression of Myc-tagged 5-HT 2C and 5-HT 4 receptors was performed by ELISA under permeabilized (Triton X-100 0.05%) vs. non-permeabilized conditions, as previously described (Chanrion et al., 2008) . Dilutions for primary antibodies were 1:2000 (Anti-Myc) and 1:500 (anti-integrin b1). Dilutions for secondary antibodies were 1:5000 (donkey anti-goat conjugated to HRP) and 1:8000 (goat anti-mouse conjugated to HRP). Immunoreactive signal was detected with a M200 Infinite plate reader (Tecan), using the SuperSignal ELISA Femto chromogenic substrate (Thermo Scientific). Control experiments were performed using cells transfected with empty vectors and values were normalized with respect to the total amount of protein.
BRET experiments
HEK-293 cells were transiently co-transfected with either pEYFP-N1-Myc-5-HT 2C or pEYFP-N1-Myc-5-HT 4 plasmids and either pcDNA3-Rluc-bARR2 or pcDNA3-Rluc-bARR2 T383A or pcDNA3-RlucbARR2 T383D plasmids for b-arrestin2 recruitment to receptors. For double brilliance b-arrestin2 assays, they were co-transfected with either pRK5-Myc-5-HT 2C or pRK5-Myc-5-HT 4 and either pCMV-Rluc8-bARR2-RGFP or pCMV-Rluc8-bARR2 T383A -RGFP or pCMV-Rluc8-bARR2 T383D -RGFP.
Cells were grown in 96-well micro-plates (6 I´10 4 cells/well) for 48 hr and starved of serum for 6 hr.
Cells were washed once with PBS and Coelenterazine H (Sigma-Aldrich) was added at a final concentration of 5 mM for 10 min. Cells were then challenged with 5-HT for 30 min. BRET readings were performed using a Mithras LB940 multimode microplate reader (Berthold Technologies, Germany) allowing sequential integration of luminescence with three filter settings: Rluc filter, 485 ± 10 nm; YFP filter, 530 ± 12.5 nm; RGFP filter, 515 ± 10 nm. Emission signals at 530 nm or 515 nm were divided by emission signals at 485 nm. The difference between this emission ratio obtained with donor and acceptor co-expressed or fused and that obtained with the donor protein expressed alone was defined as the BRET ratio. Results are expressed in milliBRET units corresponding to the BRET ratio multiplied by 1,000.
Docking
Modeling of the receptor/ß-arrestin/Erk module was made using the PRIOR method, and the PDB structures and methodology indicated in (Bourquard et al., 2015) . Structural images were made using Pymol.
Statistics
Statistical analyses were performed using Prism (v. 6.0, GraphPad Software Inc.). Unpaired t test and one-way ANOVA followed by Newman Keuls test were performed to compare two values and for multiple comparisons, respectively.
Information regarding statistical reporting
For each graph, the number of biological replicates (independent experiments performed on different sets of cultured cells) and significance of observed differences are indicated in the figure legend. The different levels of statistical significance are encoded with symbols (*, **, ***,) directly on the histograms and explained in the figure legends. The statistical tests and software used are indicated in 'Materials and methods' section. MS peptide identification probabilities were performed using the Mascot algorithm. Mascot search was performed using parameters described in the 'Material and methods' section. Mascot score represents À10*LOG10(p-value), where p-value is the absolute probability of peptide wrong assignment.
